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Abstract
Diabetes mellitus is one of the most common chronic diseases worldwide. Diabetic
cardiomyopathy (DM) is the deterioration of the myocardial function and morphology
produced by the altered glucose metabolism imposed in diabetes.  This  process  of
cardiac deterioration involves the generation of oxidative species. In the diabetic heart,
several sources contribute to the observed oxidative stress, such as xanthine oxidore‐
ductase  (XOR),  nicotinamide  adenine  dinucleotide  phosphate  (NADPH),  nitrogen
oxidases (NOX), mitochondria, and uncoupled nitric oxide synthases (NOS). A direct
consequence of  the increased production of reactive oxygen species (ROS) is  NOS
uncoupling.  This  is  the aftermath of  the oxidation of  tetrahydrobioterin (BH4),  an
essential cofactor for NOS activity. When NOS is uncoupled, its activity is redirected
toward the production of superoxide, instead of nitric oxide (NO), further contributing
to the oxidative process. This nitroso‐redox disarrangement has a direct impact on the
excitation‐contraction‐coupling  machinery  of  the  myocyte,  in  the  mitochondrial
stability  impairing energy production and favoring apoptosis,  myocardial  fibrosis,
ultimately reducing cardiac function. This review focuses on the impact of superoxide
sources in the diabetic heart and the pharmacological approaches that are currently
under investigation as possible therapeutic tools.
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1. Introduction
Diabetes mellitus is one of the most common chronic diseases worldwide [1] and continues to
increase in numbers and significance,  with characteristics of an epidemic [2],  as modern
lifestyles lead to reduced physical activity and increased obesity.
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Diabetic cardiomyopathy is the manifestation in the myocardium of the alterations pro‐
duced by the altered homeostasis of glucose metabolism [3], independent of coronary ar‐
tery disease and hypertension. This cardiomyopathy is characterized initially by diastolic
dysfunction and cardiac hypertrophy, with preserved ejection fraction [4]. As diabetes
progress, systolic dysfunction and reduced ejection fraction are developed [5]. This proc‐
ess of cardiac deterioration in diabetes includes oxidative stress [6] that results in apopto‐
sis [7–9] and fibrosis that further deteriorate the myocardium. Despite the importance of
diabetic cardiomyopathy as a clinical entity, the pathological cellular and molecular mech‐
anisms driving the adverse changes in diabetic myocardial structure and function have
not been fully resolved, but the development and progression of diabetic complications is
frequently attributed to increased oxidative stress [6].
Reactive oxygen species (ROS) consist of a variety of highly reactive oxygen‐based mole‐
cules that consist of both free radicals and chemicals capable of generating free radicals,
such as superoxide, H2O2, and peroxynitrite (ONOO−) [10]. Although in health the pri‐
mary source of ROS is the mitochondria [11], they are also produced by a range of other
sources such as xanthine oxidase, NADPH oxidases and uncoupled nitric oxide synthase
(NOS). Oxidative stress takes place when the rate of production of ROS overrides the deg‐
radation by antioxidant enzymes. An increase in ROS levels leads to a constellation of
harmful consequences by producing damage by oxidative modifications, diminishing of
nitric oxide (NO) bioavailability, and by inducing alteration in the intracellular‐signaling
pathways [12]. In a variety of studies in animal models of diabetes and humans with dia‐
betic cardiomyopathy, it has been shown that increased ROS levels [11, 13] have been as‐
sociated with the pathophysiology of heart failure, including from cardiac remodeling and
mechanical impairment [14]. This ROS‐induced damage is probably a consequence of oxi‐
dative damage to cardiac proteins and also by inducing cell death in the myocardium [8,
13, 15].
In diabetes, the resultant hyperglycemia, hyperlipidemia, and insulin resistance enhance
oxidative stress in the diabetic heart [16]. Altered glucose flux, mitochondrial dysfunction,
and nitric oxide synthase uncoupling jeopardize the diabetic myocardium, increasing the
risk of cardiac remodeling and the transition toward heart failure [3].
In the diabetic heart, the alterations in the excitation‐contraction coupling machinery are
profound [17]. The levels of the sarcoendoplasmic reticulum Ca2+ pump (SERCA) are re‐
duced [18], and total phospholamban (PLB) is increased [19], while phosphorylated phos‐
pholamban is reduced. Phospholamban is a 5 kDa protein that tonically inhibits the
activity of SERCA2. Upon activation, phospholamban is phosphorylated (by PKA or Cam‐
KII, for instance), oligomerizes, and releases SERCA of its inhibition [20]. In this condi‐
tion, Ca2+ is transported back into the sarcoplasmic reticulum at a higher rate. The
expression of the calcium release channel ryanodine receptor (RyR2) and the sodium‐calci‐
um exchanger (NCX) are reduced in general [18, 19, 21–24]. Functionally, this pattern of
protein expression is associated with impaired relaxation, increased sarcoplasmic reticu‐
lum calcium leak, and reduced contractility.
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Altered calcium handling has been characterized in the diabetic cardiac myocytes [17].
Reduced capacity of the sarcoplasmic reticulum Ca2+ pump SERCA2 results in a diminished
storage capacity of Ca2+ that impairs cardiac contractility [18, 19, 25]. Importantly, it also alters
cardiac relaxation, which is evidenced in the diastolic dysfunction.
Oxidative stress may affect Ca2+ handling in the heart, at the level of the ryanodine receptor
(RyR2) [26–28], which is the Ca2+ release channel of the sarcoplasmic reticulum. This channel
is particularly redox sensitive and has been described that oxidative modification alters it
function, leading to diastolic leak of Ca2+, with a negative impact of contractility and relaxation
[28–30].
In diabetes, several sources may contribute to the observed oxidative stress, such as xanthine
oxidoreductase (XOR) [31, 32], NADPH oxidases (NOX) [33–35], mitochondria [11], and
uncoupled nitric oxide synthases (NOS) [36, 37]. Apparently, the main source of superoxide
in the diabetic heart corresponds to XOR and NOX. These latter enzymes are present in the
heart, mainly with the isoforms NOX2 and NOX4.
A direct consequence of the increased production of ROS is the uncoupling of nitric oxide
synthase [38]. This is due to the oxidation of tetrahydrobioterin, an essential cofactor for NOS
activity [39]. When NOS is uncoupled, its activity is redirected toward the production of
superoxide, instead of NO [26], further contributing to the oxidative process.
2. NADPH oxidases NOX
Nicotinamide adenine dinucleotide phosphate oxidase enzymes (NADPH oxidases or
NOX) received growing attention as a source of ROS and particularly for their involvement
in redox signaling [40]. NOX exist in several isoforms (NOX1, 2, 4, and 5) [41]. These en‐
zymes catalyze for electron transfer from NADPH to molecular oxygen, resulting in the
generation of oxygen‐free radicals. NADPH oxidase is increased in both failing and diabet‐
ic rodent hearts [42–44]. In diabetic rodents, the upregulation of NADPH oxidase correlates
with morphological evidence of cardiac hypertrophy and upregulation of pro‐fibrotic genes
[42, 43, 45].
NOX2 is formed by the membrane‐associated p22phox and one gp91phox. The translocation
of the cytosolic regulatory subunits p40phox, p47phox, p67phox and the small G protein Rac1
(the isoform expressed in the cardiomyocyte) or Rac2 is necessary for the occurrence of
electron transfer from NADPH to oxygen. Under stimulation, for instance, with high lev‐
els of glucose or AngII, PKC is activated, leading to phosphorylation of p47phox, an event
that promotes the association of cytosolic subunits with p22phox and gp91phox [41] (Fig‐
ure 1). In the cardiovascular system, these enzymatic components are expressed in endo‐
thelial cells, smooth muscle, cardiomyocytes, and fibroblasts [41, 46].
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Figure 1. Mechanism of NADPH oxidase activation. Upon proper stimulus, Rac is activated and p47phox is phosphory‐
lated. Then p47phox binds p40phox and p67phox and along with Rac, translocate to the cell membrane, where they activate
NOX2 superoxide production.
2.1. NOX in diabetes
Several reports indicate that an increased activity of NOX, particularly NOX2 [34, 43, 47, 48]
and NOX4 [35], may be implicated in the pathophysiology of diabetic cardiomyopathy.
Hyperglycemia induces O2− generation in the heart primarily by disruption of the electron
transport chain in mitochondria, activation of NOX and uncoupling of NOS. In type‐2 diabetes,
a state of permanent oxidative stress alters mitochondrial function, impairing energy produc‐
tion and ultimately producing cardiomyocyte dysfunction. Elevated glucose levels have been
shown to stimulate NOX activity, increasing NOX‐derived superoxide production in cardiac
cells [48].
2.2. Physiological functions of NOX2
Recently, Prosser et al. elegantly demonstrated a physiological role for NOX2 in the car‐
diac myocytes, demonstrating that NOX2 activity is required to stimulate RyR2 in condi‐
tions of physiological stretching (preload). NOX2 activation upon stretching sensitizes
RyR2 increasing the rate of Ca2+ sparks [49]. This mechanism becomes dysregulated in
dystrophic cardiomyopathy [50]. Furthermore, more recently, it has been published that
NOX2 in conjunction with NOS1 are absolutely required for another cardiac physiological
response to an increase in afterload (Anrep effect) [51]. NOX2 oxidase has been implicated
in the cardiac dysfunction observed in ob/ob cardiac myocytes [34, 52].
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2.3. NOX2 and diabetic cardiomyopathy
Several lines of evidence showed a role of NOX2 in the diabetic cardiomyopathy [53, 54]. First,
NOX2 is activated and its subunits are upregulated in several models of diabetes and insulin
resistance, streptozotocin‐treated mice, ob/ob and db/db mice, and fructose‐fed rats, with
increased oxidative stress as a consequence.
Using streptozotocin‐treated mice, Roe et al. [55] described that pharmacological inhibition of
NADPH oxidase with apocynin reduced part of the cardiac damage and it improved heart
functional evaluated as fractional shortening, and cardiomyocytes mechanics, associated with
a reduction in nitrosative and oxidative stress. Nevertheless, since apocynin is not a specific
inhibitor for NOX2, these results might be ascribed also to NOX4, which is also present in the
cardiomyocyte.
Evidence for a more specific and crucial role for NOX2 came from studies using knock out for
Rac1, one of the cytosolic components of the holoenzyme complex. In cardiac‐specific Rac‐1
knockout mice, induction of diabetes by streptozotocin treatment showed reduced apoptosis,
fibrosis and improved cardiac function compared to wild‐type animals [56, 57]. The mecha‐
nisms of reduced cardiac damage involves a reduction in NADPH oxidase activity, a reduction
in mitochondrial ROS production that attenuates fetal gene program, reduces the inflamma‐
tory process, and reduces endoplasmic reticulum stress. In addition, cardiomyocyte‐specific
deletion of Rac‐1 reduces cardiac damage in diabetic mice after ischemia‐reperfusion by
reducing calpain proteolictic activity [58].
2.4. NOX4
NOX4 is expressed constitutively in the heart and its activity has been ascribed as mito‐
chondrial [59]. Its physiological role has not been clarified. On the contrary, there are de‐
scriptions of NOX4 in pathological conditions that are both beneficial [60] and deleterious
[44]. Indeed, Sadoshima’s group has shown that NOX4 is an important source of oxidative
stress in a mouse model of pressure overload (by aortic constriction). In this study, NOX4
deletion was associated with preserved ejection fraction and reduced hypertrophy, apop‐
tosis, and mitochondrial function compared to wild‐type animals [44]. Nevertheless, these
results are contrary to those observed by Shah’s group. These investigators reported a
protective role for NOX4, using the same strategy (pressure overload in a cardiomyocyte‐
specific knock‐out mouse for NOX4), with the difference that they additionally used a
mouse with cardiomyocyte‐targeted increase in NOX4, which showed an increased angio‐
genesis in response to overload [60].
Regarding diabetic cardiomyopathy, Maalouf et al. reported that NOX4 plays a pivotal role in
the cardiac damage in streptozotocin‐treated rats. They found that NOX4 was up upregulated
and when silenced using antisense oligonucleotides, this was reversed, along with the
induction of fetal program genes and fibrosis, as well as cardiac function [35].




Xanthine oxidoreductase (XOR) is a highly conserved member of the molybdoenzyme family.
It consists of a 150 kDa homodimer that is involved in the purine degradation pathway,
producing superoxide as a secondary metabolite. This precursor may further divert in the
formation of two enzymatic activities, xanthine dehydrogenase (XDH) and xanthine oxidase
(XO). XO is derived from XDH as a result of proteolisis or reversible oxidation of cysteines of
XDH. Whereas XDH reduces NAD+ to NADH, XO utilizes molecular oxygen as electron
acceptor. They differ in that XO only reduces oxygen, whereas XDH can reduce either O2 or
NAD+. Both forms catalyze the conversion of hypoxanthine to xanthine and xanthine to uric
acid. In both steps, O2− and H2O2 are produced [61]. Normally, in the cardiac myocyte, XOR is
located in the sarcoplasmic reticulum, where it regulates some features of calcium handling
and also myofilament calcium sensitivity. We have reported that XOR is upregulated in dilated
cardiomyopathy, producing oxidative stress that interferes with NO signaling, resulting in
dysregulated RyR2 activity, ultimately producing diastolic calcium leak and reducing con‐
tractility [28]. It is probably that in diabetes, XOR may impact negatively calcium handling,
but this has not been clarified.
XOR has been implicated in the pathophysiology of streptozotocin‐induced diabetic cardio‐
myopathy and its inhibition with allopurinol, oxypurinol, and antioxidants yielded some
positive results that included improvement in cardiac function, reduction in oxidative stress,
reduced cardiac apoptosis, fibrosis (collagen I), and hypertrophy [31, 33, 62]. In obese (ob/ob
mice), XOR is upregulated and its activity increased, leading to alterations in the redox state
of the heart, such as diminished GSH/GSSG ratio and decreased levels of NO metabolites [32].
Importantly, XOR has been shown to be increased in type‐1 diabetic patients [63]. In addition,
in a study in patients with type‐2 diabetes and left ventricular hypertrophy, the treatment with
allopurinol reduced left ventricular mass modestly but significantly in a period of 9 months
of treatment, in a dosage that reduced plasma uric acid by ∼50% [64].
4. Mitochondria
Due to their high‐energy demand, cardiomyocytes are abundant in mitochondria. However,
mitochondria are also an important source of ROS and NO [65, 66].
In physiological conditions, most of the reducing equivalents of the electron transport chain
are directed toward the production of ATP and about 0.1% leak and produces superoxide [11].
Diabetes induces a series of metabolic derangements in myocardial mitochondria [12]. Under
conditions of hyperglycemia, the mitochondrial inner membrane hyperpolarizes and inhibits
the electron transport in complex III, generating superoxide [67].
Myocardial diabetic damage is reduced by overexpression of Mn SOD and catalase [57, 68]
and by pharmacological inhibition of mitochondrial ROS by a mitochondrial‐directed SOD
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mimetic, mito‐Tempo [69]. Noteworthy, besides being a source of ROS, mitochondria may
suffer the consequences of increase oxidative stress as well [70]. High levels of ROS may
sensitize the mitochondrial permeability transition pore (mPTP), releasing cytochrome C, and
Smac/DIABLO ultimately inducing apoptosis [71]. The mitochondrial permeability transition
pore is constituted by the adenine nucleotide translocase (ANT), the voltage‐dependent
anionic channel (VDAC), and cyclophilin D, which under stress conditions such as high Ca2+
or increased ROS make the mitochondrial membrane permeable to ions and molecules <1500
Da, dissipating the mitochondrial membrane potential [72]. In human atrial tissue from
patients with diabetes, Anderson et al. [73] found increased H2O2 production, with increased
sensitivity to Ca2+‐induced mPTP opening compared with nondiabetic patients and also in the
heart of Zucker rats [74].
The components of the mPTP contain several redox‐sensitive sites that can be oxidized or S‐
nitrosylated [71, 72]. S‐Nitrosylation generally prevents mPTP opening, while oxidation
sensitizes to opening (Figure 2). This is consistent with the fact that NO donors, at low
concentrations, protect the mPTP from opening [72, 75, 76]. For instance, cyclophilin D has
been shown to undergo S‐nitrosylation in cysteine 203, preventing the oxidative‐induced
opening of the pore [77]. High NO donor concentrations, on the other, promote mPTP opening,
associated with oxidation rather than hypernytrosylation. Nevertheless, the role of S‐nitrosy‐
lation of mPTP in conditions of diabetic cardiomyopathy remains to be determined.
Figure 2. Potential role for nitric oxide in the mitochondrial permeability transition pore (PT). Nitric oxide produced
within the mitochondria, probably by a mtNOS, reacts with sulfhydrils groups in the pore, S‐nitrosylating them and
preventing oxidation by ROS. This prevents the pore from opening and dissipating mitochondrial protons gradient.
In addition, mitochondria appear to play a central role in diabetic cardiomyopathy through
alterations in the process of authopagie, and this process is clearly influenced by the mito‐
chondrial oxidative status [15, 78–81].




Nitric oxide (NO) is a free radical that is produced by a family of NO synthases (NOSs), using
NADPH, the amino acid L‐arginine and oxygen as substrates. NOSs are homodimers and each
subunit contains one flavin mononucleotide (FMN), one flavin adenine dinucleotide , one
tetrahydrobiopterin (BH4), and one Fe(3)‐heme cofactor that facilitates the 5‐electron oxidation
of L‐arginine to yield NO. In biological systems, NO exerts it effects by redox reactions (such
as S‐nitrosylation) or by inducing the production of cGMP as a second messenger [27, 82, 83].
Nitric oxide plays several important roles in the physiology of the myocardium, both in
cardiomyocytes and in blood vessels [83–85]. NOS1 (former neuronal NOS) and eNOS (or
NOS3) are expressed constitutively in the heart structures, particularly in the cardiomyocyte,
NOS1 participates in the regulation of contractility [86, 87] by regulating RyR2 S‐nitrosylation
[29, 30] and phospholamban phosphorylation [88, 89]. NOS1 regulates the β‐adrenergic [86,
90] and force‐frequency response [29, 91] in the heart. Also NOS1 prevents cardiac dysfunction
after a myocardial infarction and pressure overload [92–95]. For these reasons, the role for NO
in diabetic cardiomyopathy has gained attention [96–98].
5.1. NOS1
Our group has recently identified specific stimulatory influences of NOS1 on both β‐adrenergic
inotropic responses and Ca2+ transients ([Ca2+]i) using NOS1_/_ mice. These results are consistent
with in vitro studies indicating that NO regulates SR Ca2+ release via the RyR by S‐nitrosylation
of a specific thiol moiety. RyR2 activation via nitrosylation is highly sensitive to ROS. We
demonstrated non‐cGMP related, redox‐sensitive positive inotropic effects in isolated heart
preparations [82] and demonstrated the role of NOS1 specifically in SR Ca2+ cycling [29, 99].
The interplay between NO and ROS is also of critical importance for Ca2+ handling. In the SR,
NO augments RyR activity via S‐nitrosylation in a manner regulated by ROS [100, 101]. ROS
also activates the RyR2 but promotes maximal channel activity in an irreversible manner,
reducing the ability of NO to exert feedback regulation of SR Ca2+ release. Such a situation is
likely to lead to an increased Ca2+ leak through the SR and “futile” Ca2+ cycling, which increases
ATP expenditure. It is also conceivable that oxidant signaling may directly regulate cross‐
bridge cycling kinetics, thereby modulating the efficiency of contraction.
5.2. NOS1 and cardioprotection
It has been consistently documented that NOS1 exerts a protective role in the myocardium in
several model of stress, such as myocardial infarction [92, 93, 95], pressure overload [94, 102],
ischemia‐reperfusion [103], and dystrophic cardiomyopathy [104], just to mention the most
relevant. Mechanistically, NOS1 nitrosylates several proteins, including ion channels [27, 29,
105] and mitochondrial components [106], and reduces oxidative stress [107].
A key hallmark of diabetic cardiomyopathy is hypertrophy. In this process, NO may play a
role; furthermore, it has been shown that eNOS uncoupling (rather than the absence of NO)
induces hypertrophy in the model of pressure overload [108]. Recoupling eNOS with BH4
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reverses this process, but not the use of tempol, a ROS scavenger [109, 110]. In ob/ob mice,
myocardial hypertrophy has been documented [111], along with reduced NO bioavailability
associated with reduced levels of NOS1 and increased NADPH [34] and XOR activity [32].
The activity of NOS1 is required for basal phospholamban phosphorylation in the mouse
heart [88, 89], with NOS1 uncoupling resulting in an impaired ventricular relaxation and
diastolic dysfunction, as observed in a model of hypertension [112]. Conversely, an increased
production of BH4 by cardiac‐specific overexpression of GTP cyclohydrolase 1 (GCH1, the rate‐
limiting enzyme for BH4 biosynthesis), accelerates myocardial relaxation [113]. NOS1 uncou‐
pling in mdx cardiomyocytes is probably the result of the NOX2‐derived oxidative stress,
which ultimately leads to tetrahydrobioterin oxidation. With this in mind, one possibility is
that NOS1 is found in a monomeric form resulting in uncoupling. This uncoupling has been
proposed as the aftermath of excessive tetrahydrobioterin (BH4), oxidation to dihydrobioter‐
in (BH2).
5.3. NOS2
Inducible nitric oxide synthase (iNOS or NOS2) appears to play a central role in the patho‐
physiology of the diabetic cardiomyopathy [54]. In the heart, like in most tissues, iNOS is not
constitutively expressed. Inflammatory conditions trigger the activation of the nuclear factor
kappa beta (NF‐κB). The activity of iNOS has been usually ascribed as part of the nitrosative
stress. Since iNOS activity is much higher than the constitutive isoforms (NOS1 and 3), it reacts
with superoxide, producing peroxynitrite [83]. This oxidant reacts with the aromatic ring of
tyrosine residues, generating nitrotyrosine, one of the most widespread markers of nitrosative
and oxidative stress [114]. iNOS‐derived NO depresses cardiac contractility and function [115],
and has been described to be upregulated in patients with diabetic cardiomyopathy [116].
iNOS expression has been manipulated pharmacologically in diabetes, using resveratrol, a
natural polyphenol present in red wine and grapes. Reveratrol reduces the oxidative stress,
improves myocardial relaxation [117] and reduces iNOS expression in type‐2 diabetes models,
by reducing the activation of NF‐κB [118].
5.4. NOS uncoupling
In physiological conditions, NOS catalyze the reaction of oxidation of L‐arginine to produce
NO and L‐citrulline, in the presence of NADPH, oxygen, and the cofactor 6R‐5,6,7,8‐tetrahy‐
drobioterin (BH4). In the absence of BH4, electrons coming from NADPH flow to molecular
oxygen, but uncoupled of L‐arginine, producing superoxide instead of NO [26]. Apparently,
BH4 stabilizes the NOS configuration as a dimer that favors the proper flow of electrons to L‐
arginine. In its absence, NOS monomerizes and only maintains its oxidase activity [119]. BH4
and BH2 have been shown to bind to NOS with similar affinity (Kd ∼80 nM). Tetrahydrobiop‐
terin essential cofactor for aromatic amino acid hydroxylases and NOS. BH4 can be synthesized
by two pathways: de novo or recycled from its oxidized forms (Figure 3). For de novo synthesis,
GTP cyclohydrolase I (GTPCH), 6‐pyruvoyl tetrahydrobioterin synthase (PTPS), and sepiap‐
terin reductase (SR) convert GTP to BH4. In the first reaction catalyzed by GTPCH, guanosine
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5′triphosphate (GTP) is reduced to 7,8‐dihydroneopterin 3′triphosphate (DNTP), being the
rate‐limiting reaction. Next, the conversion of DNTP to 6‐pyrovoyl tetrahydrobioterin (PTP)
is catalyzed by PTPS. The final reactions are two successive propyl side‐chain reductions
catalyzed by SR [39, 120].
Figure 3. NOS uncoupling in the cardiomyocyte. Upon increased oxidative stress, BH4, which normally couples L‐argi‐
nine and NADPH oxidation and NO production, oxidized to BH2, which is unable to couple this reaction, with the
NADPH electrons passing directly to oxygen, producing superoxide.
When BH4 is oxidized to BH2, is reduced back to BH4 by the enzyme dihydrofolate reductase
(DHFR), in the salvage pathway. It is worth mentioning that during NOS catalysis BH4 is not
consumed, indicating that BH2 formation is probably the result of other oxidative processes
such as oxidative stress [39, 120].
5.5. NOS uncoupling in diabetes
It has been reported that NOS uncoupling takes places in diabetes, particularly in the vascu‐
lature [121]. For this reason, it has been associated with NOS3 [36, 37], the NOS isoform that
is dominant in the endothelium. Given that oxidative stress is increased and that cardiac
relaxation is impaired in diabetes, it is reasonable to think that NOS1 is uncoupled in the
diabetic cardiomyocyte, since this isoform is related to phospholamban phosphoryaltion.
Interestingly, it has been reported in the gastrointestinal system that diabetes produces NOS1
uncoupling, which is restored upon treatment with BH4 [122] and sepiapterin, a BH4 precursor
[123].
The first report relating NOS uncoupling and diabetes was performed in cardiomyocytes
exposed to high glucose concentration [124]. In these conditions, treatment with BH4 restored
the mechanic parameters in cardiomyocytes toward normal, an effect that could not be
obtained using tetrahydroneopterin, which also shares ROS‐scavenging properties as BH4.
Furthermore, the treatment of normal myocytes with the GTP cyclohydrolase I inhibitor 2,4‐
diamino‐6‐hydroxy‐pryrimidine (DAHP) resembled the features of myocytes under hyper‐
glycemic conditions.
The same group described that treatment of insulin‐resistant mice with the BH4 precursor folic
acid was able to produce NOS recoupling. These effects were associated with improved cardiac
function and reduction of sarcoplasmic reticulum calcium leak in isolated cardiomyocytes
[125].
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Furthermore, Jo et al. described that treatment of streptozotocin-induced diabetic mice
with the BH4 precursor sepiapterin was able to restore the intracardiac BH4 levels and re-
stored the BH4/BH2 ratio in diabetic mice. This treatment recoupled NOS in wild type,
eNOS- and nNOS-deficient mice, but not in iNOS-deficient mice, suggesting that iNOS
uncoupling was responsible for the oxidative stress observed in type-1 diabetic mice. Im-
portantly, this treatment restored ventricular function except in iNOS mice [126]. Appa-
rently, NOS uncoupling is related to the increased activity of NADPH oxidase in
streptozotocin-induced diabetic mice [55]. Furthermore, a recent report describes that in
db/db mice, a model of type-2 diabetes, the coadministration of sepiapterin and L-citrul-
line,a precursor of L-arginine restored cardiac function in diabetic hearts and improved
their response after ischemia-reperfusion [127].
6. Conclusion
In the diabetic heart, an increased hyperglycemia induced the mitochondrial production
of ROS, which favors apoptosis. Concomitantly, diabetes induces the activation of NOX
that further impairs mitochondrial function. In addition, the diabetic state induces the ex-
pression of iNOS, which in conjunction with an increased ROS production leads to the
generation of peroxynitrite, a highly oxidizing species. These elements create a feed-for-
ward system that deteriorates cardiac function at several levels. Furthermore, increased
ROS production may oxidize BH4, producing NOS uncoupling, further aggravating the
oxidative damage.
Despite the heavy burden that diabetes imposes to the heart, current therapeutic strategies do
not specifically address diabetes-induced heart failure; therefore, novel pharmacological
treatments might be of high relevance. Theoretically, a reduction in mitochondrial or NOX
derived-oxidative stress in diabetic cardiomyopathy should be able to improve some of the
features of diabetic cardiomyopathy. Nevertheless, indiscriminate NOX inhibition or ROS
quenching may have detrimental effects if the protective role of NOX4 (as opposed as other
NOXs) is disturbed, as it has been suggested in several stress conditions for the myocardium.
On the other hand, inhibitors of mitochondrial ROS production are still in their infancy and
have not been tested in humans. Therefore, pharmacological restoration of intracardiac BH4
levels may offer a new therapeutic opportunity for diabetic cardiomyopathy, as they have been
used in other pathologies, although the results have been somehow disappointing [128]. In
addition, isoform-specific NOX inhibitors are needed as pharmacological tools against diabetic
cardiomyopathy.
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